NCT06302023View on ClinicalTrials.gov

Docosahexaenoic Acid (DHA) Supplementation During Pregnancy Reduces the Risk of Preterm Birth in Threatened Preterm Labor

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 1, 2024

Primary Completion Date

October 7, 2024

Study Completion Date

October 7, 2024

Conditions

Pregnant Women Diagnosed With Threatened Preterm Labor

Interventions

DIETARY_SUPPLEMENT

Docosahexaenoic acid (DHA) 1000 mg

Pregnant women will be ask to take a DHA 1000 mg per days at bedtime until delivery or 37 week of gestational age

Trial Locations (1)

40000

KhonKaenU, Khon Kaen

All Listed Sponsors

lead

Khon Kaen University

OTHER

NCT06302023 - Docosahexaenoic Acid (DHA) Supplementation During Pregnancy Reduces the Risk of Preterm Birth in Threatened Preterm Labor | Biotech Hunter | Biotech Hunter